Early research (Phase 1)Study completedNCT05272605
What this trial is testing
Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults
Who this might be right for
SARS-CoV-2
University of Melbourne 76